2014—2016年北京大学肿瘤医院紫杉醇治疗乳腺癌的不良反应分析  

Analysis on adverse reactions induced by paclitaxel in treatment of breast cancer in Peking University Cancer Hospital from 2014 to 2016

作　　者：赵明月[1] 张艳华[1] 

机构地区：[1]北京大学肿瘤医院(北京市肿瘤防治研究所)药剂科恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《现代药物与临床》2017年第3期536-539,共4页Drugs & Clinic

摘　　要：目的分析北京大学肿瘤医院紫杉醇治疗乳腺癌时发生的不良反应,提高对紫杉醇的认识,以便更好地发挥紫杉醇的治疗作用。方法回顾并分析2014年7月—2016年12月北京大学肿瘤医院上报的81例紫杉醇治疗乳腺癌的不良反应。结果发生紫杉醇不良反应的乳腺癌患者年龄以50~59岁居多,发生时间基本出现在输注30 min内,不良反应主要症状为胸闷憋气(88.89%)、骨髓抑制(77.78%)、皮肤瘙痒(33.33%)和血压下降(33.33%)。51例为首次输注,16例发生不良反应的患者有过敏史。结论应用紫杉醇化疗的乳腺癌患者先进行预处理方案及试验量输注,可减少不良反应发生。患者输注过程中应密切关注,出现不良反应积极对症处理。Objective To improve the recognization of paclitaxel and achieve a better therapeutic effect, the adverse reactions of paclitaxel in treatment of breast cancer in Peking University Cancer Hospital were analyzed.Methods Adverse reactions （81 cases） induced by paclitaxel in treatment of breast cancer were reviewed and analyzed, which were reported from July 2014 to December 2016 in Peking University Cancer Hospital.Results Most patients with adverse reactions induced by paclitaxel in treatment of breast cancer were 50 — 59 years old. Adverse reactions mainly occurred in 30 min during infusion. The main symptoms of adverse reactions were chest tightness and dyspnea （88.89%）, bone marrow suppression （77.78%）, skin itching （33.33%）, and decreased blood pressure （33.33%）. Patients （51 cases） were first infusion of paclitaxel. There were 16 cases of patients with history of allergies.Conclusion Patients with paclitaxel-containing chemotherapy should be given pretreatment and infusion with a tested dose, which could reduce the incidence of adverse reactions. The patients should be paid attention to adverse reactions closely, and the management according to the symptoms should be performed during the infusion.

关 键 词：紫杉醇 乳腺癌 不良反应 

分 类 号：R979.1[医药卫生—药品] R984[医药卫生—药学]